Search

Your search keyword '"Hideshima T"' showing total 731 results
Start Over Author "Hideshima T"
731 results on '"Hideshima T"'

1. Lenalidomide for the treatment of relapsed and refractory multiple myeloma

Author

van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, and Anderson KC

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Niels WCJ van de Donk,1,2 Güllü Görgün,1 Richard WJ Groen,1,3 Jana Jakubikova,1 Constantine S Mitsiades,1 Teru Hideshima,1 Jacob Laubach,1 Inger S Nijhof,2 Reinier A Raymakers,2 Henk M Lokhorst,2 Paul G Richardson,1 Kenneth C Anderson11Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 2Department of Hematology, 3Department of Cell Biology, University Medical Center Utrecht, Utrecht, The NetherlandsAbstract: Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly improved the survival of patients with relapsed and refractory myeloma. The most common adverse events associated with lenalidomide include fatigue, skin rash, thrombocytopenia, and neutropenia. In addition, when lenalidomide is combined with dexamethasone or other conventional cytotoxic agents, there is an increase in the incidence of venous thromboembolic events. There is now evidence that continued treatment with lenalidomide has a significant impact on survival by improving the depth and duration of response. This highlights the value of adverse event management and appropriate dose adjustments to prevent toxicity, and of allowing continued treatment until disease progression. In this review, we will discuss the different lenalidomide-based treatment regimens for patients with relapsed/refractory myeloma. This is accompanied by recommendations of how to manage and prevent adverse events associated with lenalidomide-based therapy.Keywords: lenalidomide, multiple myeloma, immunomodulatory drugs, relapse treatment, refractory disease

Published
2012

2. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia

Author

Cholujova, D. Beke, G. Hunter, Z.R. Hideshima, T. Flores, L. Zeleznikova, T. Harrachova, D. Klucar, L. Leiba, M. Drgona, L. Treon, S.P. Kastritis, E. Dorfman, D.M. Anderson, K.C. Jakubikova, J. and Cholujova, D. Beke, G. Hunter, Z.R. Hideshima, T. Flores, L. Zeleznikova, T. Harrachova, D. Klucar, L. Leiba, M. Drgona, L. Treon, S.P. Kastritis, E. Dorfman, D.M. Anderson, K.C. Jakubikova, J.

Abstract

Waldenström macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by malignant lymphoplasmacytic cells in the bone marrow (BM). To dissect the pathophysiology of WM, we evaluated clonal cells by mapping of B cell lymphomagenesis with adaptive and innate immune tumor microenvironment (TME) in the BM of WM patients using mass cytometry (CyTOF). In-depth immunophenotypic profiling of WM cells exhibited profound expansion of clonal cells in both unswitched and switched memory B cells and also plasma cells with aberrant expression variations. WM B lymphomagenesis was associated with reduction of most B cell precursors assessed with the same clonally restricted light chain and phenotypic changes. The immune TME was infiltrated by mature monocytes, neutrophils and adaptive T cells, preferentially subsets of effector T helper, effector CTL and effector memory CTL cells that were associated with superior overall survival (OS), in contrast to progenitors of T cells and myeloid/monocytic lineage subsets that were suppressed in WM cohort. Moreover, decrease in immature B and NKT cells was related to worse OS in WM patients. Innate and adaptive immune subsets of WM TME were modulated by immune checkpoints, including PD-1/PD-L1&PD-L2, TIGIT/PVR, CD137/CD137-L, CTLA-4, BTLA and KIR expression. The response of ibrutinib treatment to the reduction of clonal memory B cell was associated with high levels of immature B cells and effector memory CTL cells. Our study demonstrates that CyTOF technology is a powerful approach for characterizing the pathophysiology of WM at various stages, predicting patient risk and monitoring the effectiveness of treatment strategies. © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Published
2023

24. Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo

Author

Navas, T A, Nguyen, A N, Hideshima, T, Reddy, M, Ma, J Y, Haghnazari, E, Henson, M, Stebbins, E G, Kerr, I, O'Young, G, Kapoun, A M, Chakravarty, S, Mavunkel, B, Perumattam, J, Luedtke, G, Dugar, S, Medicherla, S, Protter, A A, Schreiner, G F, Anderson, K C, and Higgins, L S

Published
2006
Full Text
View/download PDF

39. Targeting Myeloma Bone Disease via Activin A Inhibition: B357

Author

Vallet, S, Mukherjee, S, Vaghela, N, Pozzi, S, Santo, L, Cirstea, D, Fulciniti, M, Rahemtullah, A, Attar, E, Xie, W, Patel, C, Schoonmaker, J A, Weller, E, Hideshima, T, Munshi, N C, Seehra, J S, Scadden, D T, Anderson, K C, and Raje, N

Published
2009

50. Nano-composite Si particle formation by plasma spraying for negative electrode of Li ion batteries.

Author

Kambara, M., Kitayama, A., Homma, K., Hideshima, T., Kaga, M., Sheem, K.-Y., Ishida, S., and Yoshida, T.

Subjects
SILICON, PARTICLES, NANOCOMPOSITE materials, LITHIUM ions, LITHIUM cells, PLASMA spraying
Abstract

Nano-composite silicon powders have been produced at a maximum process throughput of 6 g/min by plasma spraying with metallurgical grade silicon powder as raw material. The obtained powders are found to be fundamentally composed of crystalline silicon particles of 20-40 nm in diameter, and are coated with an ∼5-nm-thick amorphous carbonous layer when methane gas is additionally introduced during plasma spraying. The performance of half-cell batteries containing the powders as negative electrodes has shown that the capacity decay observed for the raw Si coarse particles is significantly improved by plasma treatment. The carbonous coating potentially contributes to an improvement in capacity retention, although coexisting SiC particles that inevitably form during high-temperature processing reduce the overall capacity. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results